Please Wait
Applying Filters...
menu
    • menu
    With Fermion, start the journey of your innovative API.

    Virtual Booth

    Contact Supplier

    Suanfarma, at the Core of a Better Life.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-03-23

    Virtual Booth

    An Enquiry

    Transo-Pharm GmbH works globally to supply Active Pharmaceutical Ingredients adhering to the highest quality & GMP standards.

    Virtual Booth

    Contact Supplier

    Quotient Sciences- Molecule to Cure. Fast.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-03-23

    Virtual Booth

    An Enquiry

    Menu

    Vidofludimus Calcium

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Immunic Secures Vital European Patent For Vidofludimus Calcium
    Immunic Secures Vital European Patent For Vidofludimus Calcium

    10 Mar 2026

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/immunic-announces-grant-of-key-european-patent-protecting-relevant-dosing-regimens-for-vidofludimus-calcium-302709023.html

    PR NEWSWIRE
    10 Mar 2026
    Share Share
    Immunic To Unveil More Phase 2 Vidofludimus Calcium Data
    Immunic To Unveil More Phase 2 Vidofludimus Calcium Data

    04 Feb 2026

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/immunic-to-present-additional-phase-2-calliper-trial-data-for-vidofludimus-calcium-at-the-actrims-forum-2026-reinforcing-its-potential-in-progressive-multiple-sclerosis-302678716.html

    PR NEWSWIRE
    04 Feb 2026
    Share Share
    Immunic Highlights 2025 Accomplishments And Upcoming Milestones
    Immunic Highlights 2025 Accomplishments And Upcoming Milestones

    07 Jan 2026

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/immunic-highlights-2025-accomplishments-and-upcoming-milestones-302653601.html

    PR NEWSWIRE
    07 Jan 2026
    Share Share
    Immunic Reports Q3 2025 Financials & Corporate Update
    Immunic Reports Q3 2025 Financials & Corporate Update

    13 Nov 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/immunic-inc-reports-third-quarter-2025-financial-results-and-provides-corporate-update-302614351.html

    PR NEWSWIRE
    13 Nov 2025
    Share Share
    Immunic Showcases Vidofludimus Calcium Data At Ectrims Congress
    Immunic Showcases Vidofludimus Calcium Data At Ectrims Congress

    25 Sep 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/immunic-presented-key-vidofludimus-calcium-data-at-the-41st-congress-of-ectrims-highlighting-its-potential-in-multiple-sclerosis-302566933.html

    PR NEWSWIRE
    25 Sep 2025
    Share Share
    Immunic Gets US Patent Notice for Vidofludimus Calcium Dose
    Immunic Gets US Patent Notice for Vidofludimus Calcium Dose

    09 Sep 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/immunic-receives-notice-of-allowance-for-united-states-patent-protecting-vidofludimus-calciums-dose-strengths-in-progressive-multiple-sclerosis-302550163.html

    PR NEWSWIRE
    09 Sep 2025
    Share Share
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.